Market capitalization | $4.50b |
Enterprise Value | $4.56b |
P/E (TTM) P/E ratio | 137.41 |
EV/FCF (TTM) EV/FCF | 68.37 |
EV/Sales (TTM) EV/Sales | 13.80 |
P/S ratio (TTM) P/S ratio | 13.64 |
P/B ratio (TTM) P/B ratio | 23.91 |
Revenue growth (TTM) Revenue growth | 58.69% |
Revenue (TTM) Revenue | $330.24m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
4 Analysts have issued a ADMA Biologics, Inc. forecast:
4 Analysts have issued a ADMA Biologics, Inc. forecast:
Dec '23 | |
Current assets | 257 257 |
Fixed assets | 72 72 |
Total Assets | 329 329 |
Dec '23 | |
Equity | 135 135 |
Debt capital | 194 194 |
Total Capital | 329 329 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.
Head office | United States |
CEO | Adam Grossman |
Employees | 624 |
Founded | 2004 |
Website | www.admabiologics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.